{"entity":{"id":"nct03326791","kind":"trial","name":"Aspirin in Colorectal Cancer Liver Metastases","aka":["ASAC"],"tldr":"A phase 2/3 trial of aspirin in colorectal cancer, run by Oslo University Hospital, active but no longer recruiting.","summary":"Aspirin in Colorectal Cancer Liver Metastases is a phase 2/3, randomised interventional study registered as NCT03326791 by Oslo University Hospital, with a registry enrolment figure of 466 participants, started 2017-12-15 and due to reach its primary completion in 2022-02-01. Interventions recorded: Acetylsalicylic acid; Placebo Oral Tablet. Conditions listed: Colorectal Cancer Liver Metastases; Colorectal Cancer; Liver Metastases. Primary outcome: Disease Free Survival (DFS) after three years treatment. Sites: Denmark, Norway, Sweden. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03326791","url":"https://clinicaltrials.gov/study/NCT03326791"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["aspirin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03326791","phase":"2/3","setting":"Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer","sponsor":"Oslo University Hospital","enrolled":466,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03326791/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"drug":[{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}